-
Kenya's economy faces climate change risks: World Bank
-
AI-generated videos use Down syndrome to make sales
-
Ghana pushes for concrete slavery reparations
-
Europe risks 'total irrelevance' without sovereign tech: Cohere chief
-
AI-generated videos wield Down syndrome to make sales
-
Suspected jihadists stage deadly new attack on Niger airport
-
Man dies, trains and classes disrupted as heatwave hits France
-
Oil tankers pass Hormuz Strait after war deal: tracker
-
Swiss central bank holds interest rates, with eye on currency risks
-
S.African sentenced in 'world's largest' rhino trafficking case
-
Bank of England follows Fed in holding interest rate
-
German chemical company to cut 3,200 jobs as crisis worsens
-
Range raises $8.3M Series A to unify treasury, risk and compliance across stablecoins and fiat
-
Innovations on show at Paris Vivatech fest
-
Bird flu kills 13,000 seal pups on remote Australian island
-
New wave of anti-LGBTQ laws sweeps Africa
-
Drastic restrictions on public transport take effect in Cuba
-
Cuba approves economic reforms to boost private sector, investment: state TV
-
Robots pour cocktails and run marathons, but still can't multitask
-
Birthright citizenship helps spark US World Cup run
-
Castro gives crucial backing to Cuba reforms
-
Driving the World's Leading Supply Chains: 9 OMP Customers Named to The 2026 Gartner Top 25
-
Qantas to launch non-stop Sydney-London flights in October 2027
-
US Fed chair Warsh vows reforms as central bank signals rate hikes on horizon
-
US Federal Reserve holds rates steady, raises inflation expectations
-
Brest boss Roy dies aged 58 from cancer
-
Military salutes and K-pop madness shake up Colombia campaigning
-
Recovery of ship traffic in Hormuz limited, but signs emerge
-
England's World Cup opener puts Spanish resort on beer alert
-
Nations allege 'attacks' on science at key climate talks
-
Plague was killing hunter-gatherers 5,500 years ago: study
-
Prince Harry and family to visit UK in July: media
-
What happens when the Strait of Hormuz re-opens?
-
US retail sales beat expectations in May as energy costs stay high
-
Spain logs third-warmest year on record in 2025
-
'Heartbreaking': Afghan govt staff abandon smartphones
-
Groundbreaking US astronaut Christina Koch wins top Spanish award
-
BBC eyes compulsory redundancies in cost-cutting drive
-
Sovereignty fears dog AI enthusiasm at France's Vivatech
-
Japan puts the heat on suspected ice cream cartel
-
Sovereignty fears to dog AI enthusiasm at France's Vivatech
-
MEXC May Report: SPACEX Launchpad Oversubscribed 15.5x, US Equity Futures Volume Jumps 85%
-
MEXC Prediction Markets Launches Combo to Enable Multi-Event Combination Trading
-
'We have always won': Ebola pioneer still on front line at 84
-
Trap, neuter, release: Jakarta battles cat-astrophic stray numbers
-
US Fed set to hold rates steady at Warsh's first meeting in charge
-
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA
-
Spanish actor Javier Bardem leaves his mark on Hollywood Boulevard
-
After three sessions, SpaceX already among world's most valuable companies
-
Surging SpaceX overtakes Amazon to become 5th biggest company
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
S.F.Lacroix--CPN